A detailed history of Piershale Financial Group, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Piershale Financial Group, Inc. holds 300 shares of NBIX stock, worth $37,653. This represents 0.02% of its overall portfolio holdings.

Number of Shares
300
Previous 300 -0.0%
Holding current value
$37,653
Previous $30,000 6.67%
% of portfolio
0.02%
Previous 0.02%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 13, 2023

BUY
$106.72 - $127.06 $32,016 - $38,118
300 New
300 $0

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Piershale Financial Group, Inc. Portfolio

Follow Piershale Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Piershale Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Piershale Financial Group, Inc. with notifications on news.